Dr Michael Hayden

Guest Contributor
June 4, 2012

Dr Michael Hayden has been appointed president of global R&D and chief scientific officer for Teva Pharmaceutical Industries Ltd, Petah Tikva Israel. Hayden is currently the Canada Research Chair in Human Genetics and Molecular Medicine and Killam professor of medical genetics at the Univ of British Columbia. He is one of the world's leading experts in Huntington's disease and has extensive experience in all aspects of drug development from target identification through to clinical development and drug submission to regulatory agencies worldwide. Hayden has founded three biotech firms: NeuroVir, Aspreva Pharmaceuticals and Xenon Genetics Inc. He was the first executive hire by Dr Jeremy Levin, who took over as Teva's CEO May 9th The firm has 47,000 employees….

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.